Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, FC7.3021, Houston, TX 77030-4009, USA.
Neuro Oncol. 2011 Jan;13(1):3-13. doi: 10.1093/neuonc/noq169. Epub 2010 Dec 10.
With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.
随着最近 FDA 批准了一种用于前列腺癌的免疫疗法和另一种黑色素瘤的免疫疗法临床试验阳性，免疫疗法可能终于开始成熟。那么，它需要什么才能成为胶质母细胞瘤标准治疗的一部分呢？为了正确看待这个问题，我们总结了神经免疫学的关键背景信息，讨论了免疫疗法临床试验设计，并探讨了一些将影响神经肿瘤学中免疫疗法发展的外在因素。
